A thorough analysis of the tumor microenvironment (TME) via RNA sequencing, immunohistochemistry (IHC), depletion studies, and preclinical therapeutic modulation identified Type I Interferon (IFN) signaling as a key pathway involved in mediating the response to RT. This evidence concerns the gene IFNA1 and neoplasm.